The administration of GLP-1 in patients with type 2 diabetes reduces early left ventricular diastolic filling and left ventricular filling pressure and therefore slows the progression of diabetic cardiomyopathy [64]. Here, GLP1R is linked to diabetic cardiomyopathy.